Pacira BioSciences (NASDAQ:PCRX) Reaches New 1-Year Low at $25.89

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) shares hit a new 52-week low during trading on Monday . The stock traded as low as $25.89 and last traded at $25.91, with a volume of 57362 shares trading hands. The stock had previously closed at $26.83.

Wall Street Analyst Weigh In

PCRX has been the topic of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $45.00 target price on shares of Pacira BioSciences in a research note on Tuesday, April 9th. TheStreet raised Pacira BioSciences from a "d+" rating to a "c" rating in a report on Thursday, February 29th. Royal Bank of Canada lowered their price target on Pacira BioSciences from $53.00 to $45.00 and set an "outperform" rating on the stock in a report on Friday, March 1st. JPMorgan Chase & Co. started coverage on Pacira BioSciences in a report on Thursday, March 7th. They issued an "overweight" rating and a $45.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $57.00 target price on shares of Pacira BioSciences in a report on Monday, March 4th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $49.50.

Pacira BioSciences Trading Down 1.1 %

The stock has a market cap of $1.23 billion, a PE ratio of 32.06 and a beta of 0.76. The stock has a 50-day moving average price of $29.33 and a two-hundred day moving average price of $29.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.24 and a quick ratio of 4.17.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, meeting analysts' consensus estimates of $0.71. The firm had revenue of $181.24 million during the quarter, compared to analyst estimates of $180.60 million. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. Sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gary W. Pace sold 90,000 shares of the business's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the sale, the director now directly owns 22,127 shares of the company's stock, valued at $677,086.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the sale, the director now directly owns 22,127 shares of the company's stock, valued at approximately $677,086.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary W. Pace sold 1,066 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now directly owns 140,384 shares in the company, valued at $4,165,193.28. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company's stock.

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Pacira BioSciences by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 5,098,424 shares of the company's stock valued at $172,021,000 after acquiring an additional 141,719 shares during the period. Frontier Capital Management Co. LLC lifted its stake in Pacira BioSciences by 15.8% in the 4th quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company's stock valued at $70,332,000 after buying an additional 285,045 shares in the last quarter. Baillie Gifford & Co. lifted its stake in Pacira BioSciences by 1.0% in the 4th quarter. Baillie Gifford & Co. now owns 1,866,741 shares of the company's stock worth $72,075,000 after purchasing an additional 18,944 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Pacira BioSciences by 0.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,860,997 shares of the company's stock worth $142,031,000 after purchasing an additional 11,800 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Pacira BioSciences by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company's stock worth $47,633,000 after purchasing an additional 17,949 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.